ClinicalTrials.gg
CompletedNCT01235559Updated Nov 2, 2016

A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)

A Phase 3 interventional study of Placebo and bitopertin [RO4917838] level 1 in Schizophrenia, sponsored by Hoffmann-La Roche. Completed at 90 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-02.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
604
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Schizophrenia by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Schizophrenia · Hoffmann-La Roche.

Enrollment
4th of 16
604 · median 294
Started
2010
with 5 others
Phase 3
6 of 19
none open now
Registered
6th of 19
by date

Among the 19 studies in Schizophrenia by Hoffmann-La Roche, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2010, is one of 6 in phase 3, and was the 6th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

None of the 19 studies in Schizophrenia by Hoffmann-La Roche is open now. The open studies under Schizophrenia, anywhere →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Schizophrenia by Hoffmann-La Roche as a file.
02

Study summary

This randomized, multi-center double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 (bitopertin) in patients with sub-optimally controlled symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Diagnosis of schizophrenia
  • Clinical stability for 16 weeks (4 months) prior to randomization
  • Antipsychotic treatment stability for the past 12 weeks prior to randomization
  • With the exception of clozapine, patients are on any of the available marketed atypical or typical antipsychotic (treatment with a maximum of two antipsychotics)

Exclusion criteria

Exclusion Criteria:

  • Has treatment resistant schizophrenia as judged by the treating physician OR have failed two trials
  • Evidence that patient has uncontrolled or unstable medical disorder (e.g. cardiovascular, renal hepatic, gastrointestinal, hematologic, immunological, neurological, endocrine, metabolic or pulmonary disease)
  • Patient has a (BMI) of \<17 or >40 kg/m2, respectively)
  • Diagnosis of mental retardation or severe organic brain syndromes
  • In the investigator's judgment, a significant risk of suicide or violent behavior"
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
604 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    bitopertin [RO4917838] 1

    Drug: bitopertin [RO4917838] level 1

  • Experimental
    bitopertin [RO4917838] 2

    Drug: bitopertin [RO4917838] level 2

Interventions

06

What researchers measure

Primary outcomes

  1. Positive symptoms factor score assessed by Positive and Negative Syndrome Scale (PANSS)

    Time frame: Change from baseline to Week 12

  2. Safety (incidence of adverse events)

    Time frame: Week 12

Secondary outcomes

  1. Symptom domains of schizophrenia using Positive and Negative Syndrome Scale (PANSS)

    Time frame: Change from baseline to Week 12

  2. Disease improvement on Clinical Global Impression - Improvement (CGI-I) symptoms scale

    Time frame: Change from baseline to Week 12

  3. Disease severity on Clinical Global Impression - Severity (CGI-S) symptoms scale

    Time frame: Change from baseline to Week 12

  4. Safety (incidence of adverse events)

    Time frame: 60 weeks

07

Study locations

90 sites
  • Costa Mesa, California 92626, United States
  • Escondido, California 92025, United States
  • Granada Hills, California 91344, United States
  • La Jolla, California 92093, United States
  • Oceanside, California 92056, United States
  • San Diego, California 92103, United States
  • Torrance, California 90502, United States
  • Lauderhill, Florida 33319, United States
  • Orange City, Florida 3273, United States
  • Plantation, Florida 33317, United States
  • Atlanta, Georgia 30308, United States
  • Indianapolis, Indiana 46222, United States
  • Flowood, Mississippi 39232, United States
  • Las Vegas, Nevada 89102, United States
  • Buffalo, New York 14215, United States
  • New York, New York 10032, United States
  • Rochester, New York 14618, United States
  • Durham, North Carolina 27705, United States
  • Scranton, Pennsylvania 18503, United States
  • Austin, Texas 78754, United States
  • Irving, Texas 75062, United States
  • Salt Lake City, Utah 84106, United States
  • Bourgas, 8000, Bulgaria
  • Kazanlak, 6100, Bulgaria
  • Novi Iskar, 1282, Bulgaria
  • Pazardzhik, 4400, Bulgaria
  • Plovdiv, 4002, Bulgaria
  • Radnevo, 6260, Bulgaria
  • Rousse, 7003, Bulgaria
  • Sofia, 1606, Bulgaria
  • Baoding, 071000, China
  • Beijing, 071000, China
  • Beijing, 100083, China
  • Beijing, 100088, China
  • Changsha, 410011, China
  • Chengdu, 610041, China
  • GuangzhouGuangdong, 510370, China
  • Hangzhou, 310003, China
  • Kunming, 650032, China
  • Nanjing, 210029, China
  • Shanghai, 200030, China
  • Shanghai, 200065, China
  • Wuhan, 430060, China
  • Wuxi, 214151, China
  • Xi'an, 710032, China
  • Xi'an, 710061, China
  • Brno, 602 00, Czech Republic
  • Liberec, 460 63, Czech Republic
  • Melnik, 276 01, Czech Republic
  • Plzen, 312 00, Czech Republic
  • Praha 10, 100 00, Czech Republic
  • Praha 6, 160 00, Czech Republic
  • Praha 8 - Bohnice, 181 03, Czech Republic
  • Sternberk, 785 01, Czech Republic
  • Napoli, Campania 80131, Italy
  • Brescia, Lombardia 25123, Italy
  • Milano, Lombardia 20121, Italy
  • Milano, Lombardia 20122, Italy
  • Torino, Piemonte 10126, Italy
  • Bari, Puglia 70124, Italy
  • Pisa, Toscana 56124, Italy
  • Pisa, Toscana 56126, Italy
  • Padova, Veneto 35128, Italy
  • Chiba, 272-8516, Japan
  • Funabashi-shi, 273-8540, Japan
  • Gunma, 370-2455, Japan
  • Hiroshima-shi, 733-0864, Japan
  • Hokkaido, 060-8648, Japan
  • Kanzaki-gun, 842-0192, Japan
  • Kita-Ku, 114-0024, Japan
  • Kitakyushu-shi, 807-8556, Japan
  • Kochi-shi, 780-8535, Japan
  • Koshi-shi, 861-1116, Japan
  • Kumamoto-shi, 861-8002, Japan
  • Kurayoshi-shi, 682-0023, Japan
  • Nagoya-Shi, 463-0802, Japan
  • Omuta-shi, 836-0004, Japan
  • Sakai-shi, 590-0018, Japan
  • Sapporo-shi, 004-0841, Japan
  • Sapporo-shi, 006-0816, Japan
  • Sendai-shi, 983-0836, Japan
  • Shirakawa-shi, 961-0021, Japan
  • Tokyo, 162-8666, Japan
  • Tokyo, 187-8551, Japan
  • Toyama-shi, 939-8073, Japan
  • Toyoake-shi, 470-1192, Japan
  • Yokohama-shi, 223-0062, Japan
  • Yokohama-shi, 233-0006, Japan
  • Yokohama-shi, 246-0026, Japan
  • St. Petersburg, 190121, Russian Federation
08

References and documents

Publications

  • Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, Marques TR, Garibaldi G, Kapur S. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Lancet Psychiatry. 2016 Dec;3(12):1115-1128. doi: 10.1016/S2215-0366(16)30344-3. Epub 2016 Nov 2. PubMed 27816567 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2010
First posted
Nov 5, 2010
Start
Dec 2010
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results delay requested
Jul 6, 2016
Last update
Nov 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01235559
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 5, 2010
Start date
Dec 2010
Primary completion
Mar 2015
Completion
Mar 2015
Last update
Nov 2, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bitopertin

Start the discussion